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a b s t r a c t
Background and purpose: Many clinical trials have shown that 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitors (statins) can signiﬁcantly reduce coronary artery disease in both pri-
mary and secondary prevention. A recent study showed that aggressive lipid-lowering therapy with
strong statins could achieve coronary artery plaque regression, as evaluated with gray-scale intravascu-
lar ultrasound (IVUS). However, it is unknown whether coronary plaque regression and stabilization are
reinforced when eicosapentaenoic acid (EPA) is used with a strong statin.
Methods and subjects: We aim to assess patients with stable angina or acute coronary syndrome who
had undergone successful percutaneous coronary intervention (PCI) with integrated backscatter IVUS
(IB-IVUS) guidance. They will be randomly allocated to receive pitavastatin (4mg), or pitavastatin (4mg)
plus EPA (1800mg), and prospectively followed for 6–8 months.holesterol-lowering drugs Results: The primary endpoint will be changes in tissue characteristics in coronary plaques, evaluated by
IB-IVUS, and secondary endpoints will include absolute changes in coronary plaque volume, serum lipid
levels, and inﬂammatory markers. The safety proﬁle will also be evaluated.
Conclusions: The combination therapy of EPA andpitavastatin for regression of coronary plaque evaluated
by IB-IVUS (CHERRY) study will be the ﬁrst multicenter study using IB-IVUS to investigate the effects of
combination therapy with pitavastatin and EPA on coronary plaque volume and tissue characteristics.
© 2ntroductionThe clinical beneﬁt of cholesterol-lowering therapy with
-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
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inhibitors (statins) has been conclusively demonstrated by numer-
ous large-scale, multicenter, randomized primary and secondary
prevention clinical trials [1–5]. Furthermore, intensive lipid-
lowering therapy with strong statins can regress coronary
atherosclerosis, as shown with intravascular ultrasound (IVUS)
analysis [6–8]. The effects of intensive therapy with pitavastatin
(4mg/day) on coronary plaque regression have been reported to
be comparable with those achieved with atorvastatin (20mg/day)
in patients with acute coronary syndrome [9]. However, cardiovas-
cular events cannot be completely prevented by high-dose therapy
llege of Cardiology.
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Table 1
Inclusion criteria.
• Patients who provide voluntarily written consent after being provided with
the details of clinical trial participation
• Patients aged 20 years or older at the time of their consent
• Patients with hypercholesterolemia, as deﬁned by any of the following
criteria: (1) TC≥220mg/dL (2) LDL-C≥140mg/dl, (3) cholesterol-lowering
treatment is necessary in accordance with the investigator’s judgment when
LDL-C≥100mg/dL or TC≥180mg/dL
• Patients with stable angina or acute coronary syndrome who have received
successful PCI with IVUS guidance
• Patients with coronary plaques (≥500m in thickness or ≥20% plaque
coverage) ≥5mm from the previously treated area in the same coronary
artery branch
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Table 2
Exclusion criteria.
• Patients whose target lesion site is a coronary bypass graft
• Patients who have undergone previous PCI on the lesion site where the
IB-IVUS evaluation is planned
• Patients who may undergo PCI on the lesion site where the IB-IVUS
evaluation is planned
• Patients with familial hypercholesterolemia
• Patients with a past history of allergy to EPA and/or pitavastatin
• Patients with hepatic dysfunction (ALT 100 IU/L or more) and/or biliary
obstruction
• Patients with renal dysfunction (serum creatinine 2.0mg/dL or more) or
undergoing dialysis
• Patients deemed ineligible for the study by physicians
laboratory tests at 1, 3, and 6–8 months after enrollment. The
Assessment Committee will evaluate MACE and any other adverse
events.
CAG, PCI 
and IB-IVUS
Informed
consent Randomized
Pitavastatin 4 mg/day
Pitavastatin 4 mg/day
+ EPA 1800 mg/day
CAG and 
IB-IVUS
1 week 6~8 monthsCC, total cholesterol; LDL-C, low-density lipoprotein-cholesterol; PCI, percutaneous
oronary intervention; IVUS, intravascular ultrasound.
ith strong statins [10]. This residual risk has gained increasing
ttention in statin-treated secondary prevention patients [11].
Epidemiological and clinical evidence suggest a signiﬁcant
nverse association between long-term intake of long-chain n-3
olyunsaturated fatty acids, especially eicosapentaenoic acid (EPA)
nd docosahexaenoic acid (DHA), and mortality due to coronary
rtery disease [12–18]. In JELIS (Japan eicosapentaenoic acid lipid
ntervention study), EPA signiﬁcantly reduced coronary events in
atients with hypercholesterolemia under statin treatment [19].
PA is especially effective for secondary prevention of coronary
rtery disease [20]. Because standard statins, such as pravastatin or
imvastatin, were used in the JELIS trial, it is unclear whether there
re additional effects of EPA in coronary artery disease patients
ndergoing treatment with high-doses of strong statins.
The evaluation of coronary atherosclerosis progression-
egression by IVUS is reported to be a feasible surrogate endpoint
o predict future cardiovascular events [21,22]. Although coronary
laque has been evaluated by gray-scale IVUS, it remains unclear
hether coronary plaque tissue characteristics change over time.
ntegrated backscatter IVUS (IB-IVUS) has recently been developed
nd allows analysis of speciﬁc tissue components (calciﬁcation,
ense ﬁbrosis, ﬁbrosis, lipid pool) of coronary plaques in vivo
23–25]. IB-IVUS has also proved useful for assessing the prog-
osis of patients with coronary atherosclerosis and the risk of
xperiencing a coronary event [26–28].
The present study was designed to evaluate the effects of com-
ination therapy consisting of high-dose pitavastatin and EPA on
oronary plaque tissue characteristics using IB-IVUS.
aterials and methods
tudy design
All procedures will be in accordance with the principles
escribed in the Declaration of Helsinki. The CHERRY study will
e a randomized, non-blinded, parallel group study. Patients who
atisfy all inclusion criteria will be enrolled after undergoing
uccessful percutaneous coronary intervention (PCI) under IVUS
uidance to treat stable angina or an episode of acute coronary
yndrome (Table 1). Patients with any of the exclusion criteria
Table 2) will not be enrolled. Included patients will provide writ-
en informed consent before they are randomly allocated to receive
ither pitavastatin (4mg daily) or pitavastatin and EPA (4mg and
800mg daily, respectively) (Fig. 1). The supervising physician
ill administer the allocated drugs within one week of success-
ul PCI. The participants will continue taking the allocated drugs
ntil the end of study or when certain endpoints aremet, including
eath, any cardiovascular event, any adverse event, or discontinued
articipation in the study. Administration of cholesterol-lowering
rugs such as other statins, ﬁbrates, probucol, niacin, colestimide,PCI, percutaneous coronary intervention; IB-IVUS, integrated backscatter intravas-
cular ultrasound; EPA, eicosapentaenoic acid; ALT, alanine aminotransferase.
and ezetimibe, and supplementation of n-3 polyunsaturated fatty
acids are prohibited during the present study. Investigators will
follow up the participants for 6–8 months at six centers and will
conduct medical examinations, blood testing, IVUS, and coronary
angiography (CAG). Patient enrollment is planned for between
September 2009 and April 2014 and may be extended if neces-
sary. The study has been registered at University Hospital Medical
Information Network (UMIN) (UMIN ID: 000002815).
Endpoints
The primary endpoint will be the change of coronary plaque tis-
sue characteristics as evaluated by IB-IVUS. Secondary endpoints
include: (1) changes in the volume and minimum intravas-
cular lumen diameter of target coronary plaques; (2) changes
in total cholesterol (TC), low-density lipoprotein-cholesterol
(LDL-C), triglyceride (TG), high-density lipoprotein-cholesterol
(HDL-C), malonyldialdehyde LDL (MDA-LDL), remnant-like
particle-cholesterol (RLP-C), lipoprotein (a), and apoliproteins
(Apo A-I, Apo B, Apo E); (3) changes in EPA/arachidonic acid
levels; (4) changes in high sensitivity C-reactive protein (hs-CRP);
(5) changes in coronary plaque volume, minimum intravascular
lumen diameter, and % stenosis at the site of the lesion where
the coronary plaque is evaluated; and (6) the incidence of major
adverse cardiovascular events (MACE) deﬁned as cardiac death,
nonfatal myocardial infarction, PCI, or coronary artery bypass
grafting.
Safety monitoring
Safety will be evaluated by regular medical examinations andFig. 1. Flow chart of the study timeline. EPA, eicosapentaenoic acid; IB-IVUS,
integrated backscatter intravascular ultrasound; CAG, coronary angiography; PCI,
percutaneous coronary intervention.
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ample size calculation
The aim of this study is to investigate differences between
atients treated with pitavastatin and pitavastatin supplemented
ith EPA in terms of changes in coronary artery plaque compo-
ition as measured by IB-IVUS. There is currently no information
n the literature regarding the effects of pitavastatin supplemented
ith EPA on coronary artery plaque. The study group estimated the
ecessary sample size based on the effect of EPA or ﬁsh oil supple-
entation on carotid plaque regression [29,30], and 100 patients in
achgrouparenecessary toachieve80%powerbya two-sided, two-
ample t-test at a signiﬁcance level of 5%. Assuming a 10% drop-out
ate, the desired sample size per group is 110 patients.
ata management
Patient information, blood samples, and IB-IVUS images will
e coded with a study identiﬁcation number, and the key code
or individual identity will remain blinded. Serum lipids, RLP-C,
polipoproteins, and hs-CRP will be measured using routine labo-
atory methods. MDA-LDL and fatty acid fraction will be measured
t SRL Co., Ltd. (Tokyo, Japan). IB-IVUS and CAG images will be
uantitatively analyzed at the core laboratory by an independent
xperienced investigator who is unaware of the patient groups.
aseline and follow-up IVUS images will be reviewed together on a
isplay, and target segments will be selected. One target segment
ill be determined at a non-PCI site (>5mm proximal or distal to
he PCI site)with a reproducible index side branchon the PCI vessel.
tatistical analysis
Continuous variables, such as laboratory data, are expressed as
hemean± standard deviation (SD) for eachperiod. Group compar-
sons between the pitavastatin and pitavastatin and EPA groupwill
e calculated by Student’s t-tests, analyses of variance (ANOVAs),
hi-square tests, Fisher’s exact tests, or Mann–Whitney U-tests,
s appropriate. When an adjustment for multiplicity of testing is
ecessary, a closed testing procedure in which the test for each
omponent is performed in the order of calciﬁcation, dense ﬁbrosis,
brosis, and lipid pool; the signiﬁcance level will be 5%. Statistical
nalyses are performed using a standard software package (JMP
ersion 8; SAS Institute Inc., Cary, NC, USA).
tudy organization
Principal Investigator: Isao Kubota, Department of Cardiology,
ulmonology, and Nephrology, Yamagata University School of
edicine, Yamagata, Japan.
Biostatistician: Akira Fukao, Department of Public Health, Yam-
gata University Graduate School of Medical Science, Yamagata,
apan.
Core Laboratory: Osamu Hirono, Yamagata Prefectural Shinjyo
ospital, Yamagata, Japan.
Assessment Committee: Motoyuki Matsui, Yamagata Prefec-
ural Central Hospital, Yamagata, Japan.
iscussion
Recent large-scale clinical trials such as ORIGIN and OMEGA
evealed that supplementation with n-3 polyunsaturated fatty
cids containing EPA and DHA did not show additional effects
or primary and secondary prevention of coronary artery disease
31,32]. However, clinical and experimental studies showed that
PA potentially reduces and stabilize atherosclerosis [19,33]. The
HERRYstudywill be theﬁrstmulticenter studyemploying IB-IVUS
o evaluate the effects of EPA and pitavastatin on coronary artery
[diology 64 (2014) 236–239
plaque composition. The study group will investigate the relation-
ship between changes in plaque composition and lipid levels in
patients with stable angina or acute coronary syndrome receiv-
ing EPA and pitavastatin. Furthermore, the study group hopes to
demonstrate theprocessof coronaryarteryplaquestabilizationand
determine whether EPA reduces residual risk in patients treated
with high-dose strong statin for secondary prevention.
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